MTC 896

Drug Profile

MTC 896

Alternative Names: MTC896

Latest Information Update: 12 Jun 2015

Price : $50

At a glance

  • Originator Mimetica
  • Class Hormones; Skin disorder therapies
  • Mechanism of Action Melanocortin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acne vulgaris

Most Recent Events

  • 10 Apr 2017 Mimetica plans a clinical trial for Acne vulgaris (In volunteers) in Australia (ACTRN12617000498392p)
  • 01 Apr 2015 Mimetica initiates enrolment in a phase II trial for Acne vulgaris in USA (NCT02395549)
  • 27 Mar 2015 Mimetica plans to initiate a phase II trial in Acne vulgaris in USA (NCT02395549)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top